Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application ertugliflozin tablets, 5mg and 15mg. Aurobindo Pharma’s ertugliflozin tablets are an AB-rated generic equivalent to the reference listed drug (RLD), STEGLATRO Tablets manufactured by Merck Sharp & Dohme LLC (Merck).
Ertugliflozin tablets, are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Ertugliflozin tablets, has an estimated market size of US $269.7 Million for the twelve months ending May 2023, as per IQVIA.
